EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 692-706

  Pallis, A G ^a   Gridelli, C ^b   van Meerbeeck, J P ^a,c   Greillier, L ^a,d   Wedding, U ^e   Lacombe, D ^a   Welch, J ^a   Belani, C P ^f   Aapro, M ^g  

^a EORTC DATA CENTER   (Belgium)

^b S G MOSCATI HOSPITAL   (Italy)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f PENN STATE CANCER INSTITUTE   (United States)

^g CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Age; Elderly; EORTC; Experts' opinion; Lung cancer; NSCLC; SIOG

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX;

ADJUVANT THERAPY; ADVANCED CANCER; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; ELDERLY CARE; ESOPHAGITIS; EVIDENCE BASED MEDICINE; GERIATRICS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TOXICITY; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ONCOLOGY; OVERALL SURVIVAL; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THORACOTOMY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 77951498205     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp360     Document Type: Review

References (150)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997; 33: 2313-2314.
3. Havlik RJ, Yancik R, Long S et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74: 2101-2106.
4. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000; 36: 1741-1754.
5. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
6. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626-4631.
7. Ramsey SD, Howlader N, Etzioni RD et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004; 22: 4971-4978.
8. Owonikoko TK, Ragin CC, Belani CP et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007; 25: 5570-5577.
9. Townsley C, Pond GR, Peloza B et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005; 23: 3802-3810.
10. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003; 41: 245-258.
11. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112-3124.
12. Townsley CA, Chan KK, Pond GR et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer 2006; 6: 34.
13. Basche M, Baron A, Eckhardt SG et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract 2008; 4: 162-168.
14. Janssen-Heijnen ML, Smulders S, Lemmens VE et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004; 59: 602-607.
15. O'Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol 2004; 11: 962-969.
16. Ciriaco P, Zannini P, Carretta A et al. Surgical treatment of non-small cell lung cancer in patients 70 years of age or older. Int Surg 1998; 83: 4-7.
17. Hanagiri T, Muranaka H, Hashimoto M et al. Results of surgical treatment of lung cancer in octogenarians. Lung Cancer 1999; 23: 129-133.
18. Thomas P, Piraux M, Jacques LF et al. Clinical patterns and trends of outcome of elderly patients with bronchogenic carcinoma. Eur J Cardiothorac Surg 1998; 13: 266-274.
19. Pagni S, McKelvey A, Riordan C et al. Pulmonary resection for malignancy in the elderly: is age still a risk factor? Eur J Cardiothorac Surg 1998; 14: 40-44.
20. Oliaro A, Leo F, Filosso PL et al. Resection of bronchogenic carcinoma in the elderly. J Cardiovasc Surg (Torino) 1999; 40: 715-719.
21. Sioris T, Salo J, Perhoniemi V et al. Surgery for lung cancer in the elderly. Scand Cardiovasc J 1999; 33: 222-227.
22. Kamiyoshihara M, Kawashima O, Ishikawa S et al. Long-term results after pulmonary resection in elderly patients with non-small cell lung cancer. J Cardiovasc Surg (Torino) 2000; 41: 483-486.
23. Conti B, Brega Massone PP, Lequaglie C et al. Major surgery in lung cancer in elderly patients? Risk factors analysis and long-term results. Minerva Chir 2002; 57: 317-321.
24. Yamamoto K, Padilla AJ, Calvo M et al. Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients. Eur J Cardiothorac Surg 2003; 23: 21-25.
25. Birim O, Zuydendorp HM, Maat AP et al. Lung resection for non-small-cell lung cancer in patients older than 70: mortality, morbidity, and late survival compared with the general population. Ann Thorac Surg 2003; 76: 1796-1801.
26. Sawada S, Komori E, Nogami N et al. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition. Chest 2005; 128: 1557-1563.
27. Mery CM, Pappas AN, Bueno R et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest 2005; 128: 237-245.
28. Yazgan S, Gursoy S, Yaldiz S et al. Outcome of surgery for lung cancer in young and elderly patients. Surg Today 2005; 35: 823-827.
29. Muraoka M, Oka T, Akamine S et al. Surgical treatment for lung cancer in octogenarians. Surg Today 2005; 35: 725-731.
30. Matsuoka H, Okada M, Sakamoto T et al. Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. Eur J Cardiothorac Surg 2005; 28: 380-383.
31. Cerfolio RJ, Bryant AS. Survival and outcomes of pulmonary resection for non-small cell lung cancer in the elderly: a nested case-control study. Ann Thorac Surg 2006; 82: 424-429.
32. Dominguez-Ventura A, Cassivi SD, Allen MS et al. Lung cancer in octogenarians: factors affecting long-term survival following resection. Eur J Cardiothorac Surg 2007; 32: 370-374.
33. Sullivan V, Tran T, Holmstrom A et al. Advanced age does not exclude lobectomy for non-small cell lung carcinoma. Chest 2005; 128: 2671-2676.
34. Sirbu H, Schreiner W, Dalichau H et al. Surgery for non-small cell carcinoma in geriatric patients: 15-year experience. Asian Cardiovasc Thorac Ann 2005; 13: 330-336.
35. Dyszkiewicz W, Pawlak K, Gasiorowski L. Early post-pneumonectomy complications in the elderly. Eur J Cardiothorac Surg 2000; 17: 246-250.
36. Aoki T, Yamato Y, Tsuchida M et al. Pulmonary complications after surgical treatment of lung cancer in octogenarians. Eur J Cardiothorac Surg 2000; 18: 662-665.
37. Brock MV, Kim MP, Hooker CM et al. Pulmonary resection in octogenarians with stage I nonsmall cell lung cancer: a 22-year experience. Ann Thorac Surg 2004; 77: 271-277.
38. Port JL, Kent M, Korst RJ et al. Surgical resection for lung cancer in the octogenarian. Chest 2004; 126: 733-738.
39. Spaggiari L, Scanagatta P. Surgery of non-small cell lung cancer in the elderly. Curr Opin Oncol 2007; 19: 84-91.
40. Sigel K, Bonomi M, Packer S et al. Effect of age on survival of clinical stage I non-small-cell lung cancer. Ann Surg Oncol 2009; 16: 1912-1917.
41. van Rens MT, de la Riviere AB, Elbers HR et al. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117: 374-379.
42. Wada H, Nakamura T, Nakamoto K et al. Thirty-day operative mortality for thoracotomy in lung cancer. J Thorac Cardiovasc Surg 1998; 115: 70-73.
43. Rostad H, Strand TE, Naalsund A et al. Lung cancer surgery: the first 60 days. A population-based study. Eur J Cardiothorac Surg 2006; 29: 824-828.
44. Janssen-Heijnen ML, Maas HA, Houterman S et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 2007; 43: 2179-2193.
45. Jaklitsch MT, Mery CM, Audisio RA. The use of surgery to treat lung cancer in elderly patients. Lancet Oncol 2003; 4: 463-471.
46. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-622.
47. van Meerbeeck JP, Damhuis RA, Vos de Wael ML. High postoperative risk after pneumonectomy in elderly patients with right-sided lung cancer. Eur Respir J 2002; 19: 141-145.
48. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56: 89-108.
49. Yim AP. VATS major pulmonary resection revisited-controversies, techniques, and results. Ann Thorac Surg 2002; 74: 615-623.
50. Jaklitsch MT, DeCamp MM Jr., Liptay MJ et al. Video-assisted thoracic surgery in the elderly. A review of 307 cases. Chest 1996; 110: 751-758.
51. Yim AP. Thoracoscopic surgery in the elderly population. Surg Endosc 1996; 10: 880-882.
52. McVay CL, Pickens A, Fuller C et al. VATS anatomic pulmonary resection in octogenarians. Am Surg 2005; 71: 791-793.
53. Igai H, Takahashi M, Ohata K et al. Surgical treatment for non-small cell lung cancer in octogenarians-the usefulness of video-assisted thoracic surgery. Interact Cardiovasc Thorac Surg 2009; in press.
54. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
55. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
56. Douillard JY, Rosell R, De LM et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727.
57. Pignon JP, Tribodet H, Scagliotti GV et al. Lung Adjuvant Cisplatin Evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008; 26: 3552-3559.
58. Fruh M, Rolland E, Pignon JP et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008; 26: 3573-3581.
59. Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95: 1453-1461.
60. Waller D, Peake MD, Stephens RJ et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26: 173-182.
61. Pepe C, Hasan B, Winton TL et al. Adjuvant vinorelbine and cisplatin in elderly patients: national Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25: 1553-1561.
62. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352: 257-263.
63. Burdett S, Stewart L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005; 47: 81-83.
64. Mayer R, Smolle-Juettner FM, Szolar D et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest 1997; 112: 954-959.
65. Dautzenberg B, Arriagada R, Chammard AB et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 1999; 86: 265-273.
66. Feng QF, Wang M, Wang LJ et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2000; 47: 925-929.
67. Okawara G, Ung YC, Markman BR et al. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2004; 44: 1-11.
68. Pisters KM, Evans WK, Azzoli CG et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007; 25: 5506-5518.
69. Hurria A, Kris MG. Management of lung cancer in older adults. CA Cancer J Clin 2003; 53: 325-341.
70. Sibley GS, Jamieson TA, Marks LB et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 1998; 40: 149-154.
71. Cheung PC, Mackillop WJ, Dixon P et al. Involved-field radiotherapy alone for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000; 48: 703-710.
72. Gauden SJ, Tripcony L. The curative treatment by radiation therapy alone of Stage I non-small cell lung cancer in a geriatric population. Lung Cancer 2001; 32: 71-79.
73. Hayakawa K, Mitsuhashi N, Katano S et al. High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer. Lung Cancer 2001; 32: 81-88.
74. Patterson CJ, Hocking M, Bond M et al. Retrospective study of radiotherapy for lung cancer in patients aged 75 years and over. Age Ageing 1998; 27: 515-518.
75. Pignon T, Gregor A, Schaake KC et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 1998; 46: 239-248.
76. Berman AT, Rengan R. New approaches to radiotherapy as definitive treatment for inoperable lung cancer. Semin Thorac Cardiovasc Surg 2008; 20: 188-197.
77. McGarry RC, Papiez L, Williams M et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005; 63: 1010-1015.
78. Onishi H, Araki T, Shirato H et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101: 1623-1631.
79. Gridelli C, Maione P, Rossi A. Treatment of stage I-III non-small-cell lung cancer in the elderly. Oncology (Williston Park) 2006; 20: 373-380.
80. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
81. Curran WJ, Scott CB, Langer CJ. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III NSCLC: rTOG 9410. Proc Am Soc Clin Oncol 2003; 22: (Abstr 2499).
82. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98.
83. Pierre F, Perol M, Gilles R. A randomized phase III trial of sequential chemoradiotherapy versus concurrent chemoradiotherapy in locally advanced NSCLC (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 2001; 20: (Abstr 1246).
84. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
85. Edelman MJ, Tang M, Gardner JF et al. Therapy (Tx) of locally advanced (LA) NSCLC in the elderly: analysis of 6,325 patients from Surveillance, Epidemiology and End Results (SEER)-Medicare. Proc Am Soc Clin Oncol 2008; 26: (Abstr 7549).
86. Atagi S, Kawahara M, Tamura T et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 2005; 35: 195-201.
87. Werner-Wasik M, Scott C, Cox JD et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000; 48: 1475-1482.
88. Movsas B, Scott C, Sause W et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999; 45: 1143-1149.
89. Langer C, Scott C, Byhatdt R et al. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LA-NSCLC). Lung Cancer 2000; 29: 104.
90. Langer CJ, Hsu C, Curran W et al. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy. secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 2002; 21: (Abstr 1193).
91. Rocha Lima CM, Herndon JE, Kosty M et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002; 94: 181-187.
92. Schild SE, Stella PJ, Geyer SM et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003; 21: 3201-3206.
93. Sgroi MM, Neubauer M, Ansari R et al. An analysis of eldelry patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in patiens with stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2007; 25: (Abstr 9037).
94. Gridelli C, Maione P, Rossi A et al. Treatment of locally advanced non-small cell lung cancer in the elderly. Curr Opin Oncol 2005; 17: 130-134.
95. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91: 66-72.
96. Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24: 3657-3663.
97. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 2529-2536.
98. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 2001; 34 (4 Suppl): S65-S69.
99. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
100. Russo A, Rizzo S, Fulfaro F et al. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 2009; 115: 1924-1931.
101. Tsukada H, Yokoyama A, Nishiwaki Y et al. Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in eldelry patients (pts) with advanced non-small cell lung cancer (NSCLC): jCOG0207. Proc Am Soc Clin Oncol 2007; 25: (Abstr 7629).
102. Ardizzoni A, Boni L, Tiseo M et al. Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857.
103. Sederholm C, Hillerdal G, Lamberg K et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23: 8380-8388.
104. Lilenbaum RC, Herndon JE, List MA et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190-196.
105. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.
106. Langer C, Vangel M, Schiller HJ et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 2003; 22: (Abstr 2571).
107. Kelly K, Giarritta S, Akerley W et al. Should older patients (Pts) receive combination chemotherapy for advanced stage Non-Small Cell Lung Cancer (NSCLC)? An Analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20: (Abstr 1313).
108. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005; 104: 2766-2774.
109. Hensing TA, Peterman AH, Schell MJ et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98: 779-788.
110. Goto K, Nishiwaki Y, Saijo N et al. The Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC): a subgroup analysis in eldelry patients (pts). Proc Am Soc Clin Oncol 2006; 24: (Abstr 7115).
111. Ansari R, Gonin R, Socinski M et al. Eldelry subgroup analysis of a radnomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer. Proc Am Soc Clin Oncol 2007; 25: (Abstr 7665).
112. Fossella F, Pereira JR, von PJ et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
113. Ramalingam S, Perry MC, La Rocca RV et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008; 113: 542-546.
114. Gridelli C, Maione P, Illiano A et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol 2007; 25: 4663-4669.
115. Pallis AG, Polyzos A, Boukovinas I et al. Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience. J Thorac Oncol 2008; 3: 505-510.
116. Provencio M, Camps C, Cantos B et al. Non-small cell lung cancer in the elderly. J Thorac Oncol 2007; 2: (Abstr PD4-2-7).
117. Oxnard GR, Fidias P, Muzikansky A et al. Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol 2007; 2: 1029-1035.
118. Hesketh PJ, Lilenbaum RC, Chansky K et al. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Thorac Oncol 2007; 2: 494-498.
119. Altundag O, Stewart DJ, Fossella FV et al. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2007; 2: 141-146.
120. Lichtman SM, Wildiers H, Chatelut E et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 2007; 25: 1832-1843.
121. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
122. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26: 60-65.
123. Gridelli C. Treatment of advanced non small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. J Clin Oncol 2008; 26: 13-15.
124. Crino L, Cappuzzo F, Zatloukal P et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008; 26: 4253-4260.
125. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 760-766.
126. Gridelli C, Morabito A, Gebbia V et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer. The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer 2009; in press.
127. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-2362.
128. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
129. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
130. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
131. Weiss GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 4405-4411.
132. Wheatley-Price P, Ding K, Seymour L et al. Erlotinib for advanced non-small- cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 2350-2357.
133. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
134. Wingo PA, Cardinez CJ, Landis SH et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003; 97: 3133-3275.
135. Deppermann KM. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 2001; 33 (1 Suppl): S115-S120.
136. Launay-Vacher V, Chatelut E, Lichtman SM et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007; 18: 1314-1321.
137. Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol 1992; 32: 271-302.
138. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997; 13: 169-183.
139. Nurgalieva Z, Xia R, Liu CC et al. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung sancer. Am J Ther 2009; in press.
140. Blower P, de WR, Goodin S et al. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005; 55: 117-142.
141. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007; 32: 169-175.
142. Wolfson C, Wolfson DB, Asgharian M et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111-1116.
143. Seeman TE, Berkman LF, Kohout F et al. Intercommunity variations in the association between social ties and mortality in the elderly. A comparative analysis of three communities. Ann Epidemiol 1993; 3: 325-335.
144. Landi F, Zuccala G, Gambassi G et al. Body mass index and mortality among older people living in the community. J Am Geriatr Soc 1999; 47: 1072-1076.
145. Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev 2005; 31: 380-402.
146. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG et al. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 2007; 43: 2161-2169.
147. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502.
148. Wymenga M, Biesma B, Vincent A et al. Can baseline complete geriatric assessment (CGA) predict toxicity in elderly non-small cell lung cancer (NSCLC) patients (pts) receiving combination chemotherapy? Results from the first 100 pts in the prospective multicenter NVALT-3 study. Proc Am Soc Clin Oncol 2007; 25: (Abstr 7537).
149. Extermann M, Aapro M, Bernabei R et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241-252.
150. Soubeyran P, Bellera CA, Gregoire F et al. Validation of a screening test for elderly patients in oncology. J Clin Oncol 2008; 26: (Abstr 20568).